From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Quest Diagnostics Launches Zika Antibody Test Service

by Global Biodefense Staff
September 21, 2016
Zika Virus Diagnostics and Countermeasure Development

Zika Virus Diagnostics and Countermeasure DevelopmentQuest Diagnostics today announced the availability of a new  antibody test service that aids the diagnosis of infection with the Zika virus.

The service is based on the Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), developed by the Centers for Disease Control and Prevention (CDC) and authorized for emergency use by the U.S. Food and Drug Administration (FDA). The CDC has licensed the test to Quest Diagnostics and other select national reference laboratories to aid the response to the Zika emergency in the United States.

With the new service, Quest Diagnostics now provides access to Zika virus antibody and molecular laboratory test services for people in the United States and Puerto Rico.

Quest Diagnostics was the first commercial laboratory to receive FDA emergency use authorization for a Zika test, on April 28, 2016. That molecular test is intended for the qualitative detection of RNA from Zika virus in human serum specimens. On September 6, Quest expanded its molecular Zika test capabilities with the introduction of an RT-PCR Zika test service for the qualitative detection of RNA from Zika virus in serum and paired urine specimens.

Molecular RT-PCR tests identify the presence of Zika virus RNA in a specimen, while antibody serology tests identify the presence of antibodies created by the body in response to infection. Molecular RT-PCR testing is most useful up to 14 days after the onset of symptoms, depending on sample type and other factors, while IgM antibody testing is most useful two to 12 weeks following the onset of symptoms.

“Quest now provides physicians and patients with access to a robust, complementary range of Zika test options for aiding diagnosis of Zika infection,” said Rick L. Pesano, M.D., Ph.D., vice president, research and development, Quest Diagnostics. “Quest’s national scale, diagnostic expertise and relationships with half the country’s physicians may be an increasingly important complement to public health response should the number of suspected Zika cases and demand for testing grow in the United States.

Quest operates approximately 2,300 patient service centers across the United States, more than any other commercial laboratory provider. Approximately 260 of these centers are in Florida, the first state to document cases of local transmission. Patients can provide specimens for testing at any one of these centers with a physician test order.

In addition, many healthcare providers can also collect patient specimens in their offices for testing by Quest Diagnostics. Quest Diagnostics serves half the physicians and hospitals in the United States each year.

“Commercial labs such as Quest Diagnostics can play an essential role in public health response to emerging infectious diseases like Zika,” said Scott Becker, executive director, Association of Public Health Laboratories. “These organizations bring expertise, scale and logistics support, as well as access to healthcare providers and patients, that complement and extend the capabilities of our nation’s public health labs.”

Quest Diagnostics performs testing for its proprietary Zika RT-PCR test as well as the CDC-based Zika MAC-ELISA test at its Focus Diagnostics laboratory, a reference laboratory business of Quest Diagnostics in San Juan Capistrano, Calif. Quest performs the molecular RT-PCR Zika test for use on serum and paired urine specimens at its advanced laboratory in Chantilly, Virginia.

From Our Partners
Tags: Emergency Use AuthorizationEmerging ThreatsZika

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC